TIMOPTIC Drug Patent Profile

Which patents cover Timoptic, and when can generic versions of Timoptic launch?

Timoptic is a drug marketed by Bausch And Lomb Inc and is included in three NDAs.

The generic ingredient in TIMOPTIC is timolol maleate. There are fifteen drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the timolol maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Timoptic

A generic version of TIMOPTIC was approved as timolol maleate by MYLAN on June 8^th, 1990.

Summary for TIMOPTIC

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	30
Clinical Trials:	19
Patent Applications:	5,143
Drug Prices:	Drug price information for TIMOPTIC
Drug Sales Revenues:	Drug sales revenues for TIMOPTIC
What excipients (inactive ingredients) are in TIMOPTIC?	TIMOPTIC excipients list
DailyMed Link:	TIMOPTIC at DailyMed

See drug prices for TIMOPTIC

Recent Clinical Trials for TIMOPTIC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bausch & Lomb Incorporated	N/A
University of California, San Diego	N/A
VA Office of Research and Development	Phase 3

See all TIMOPTIC clinical trials

Pharmacology for TIMOPTIC

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for TIMOPTIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	TIMOPTIC	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	018086-001	Approved Prior to Jan 1, 1982	AT1	RX	Yes	No
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-002	Nov 5, 1986	AT3	RX	Yes	Yes
Bausch And Lomb Inc	TIMOPTIC	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	018086-002	Approved Prior to Jan 1, 1982	AT1	RX	Yes	No
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-001	Nov 5, 1986	AT3	RX	Yes	Yes
Bausch And Lomb Inc	TIMOPTIC-XE	timolol maleate	SOLUTION, GEL FORMING/DROPS;OPHTHALMIC	020330-002	Nov 4, 1993	AB	RX	Yes	No

Expired US Patents for TIMOPTIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb Inc	TIMOPTIC	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	018086-002	Approved Prior to Jan 1, 1982	4,195,085
Bausch And Lomb Inc	TIMOPTIC	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	018086-001	Approved Prior to Jan 1, 1982	3,655,663
Bausch And Lomb Inc	TIMOPTIC	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	018086-002	Approved Prior to Jan 1, 1982	3,655,663
Bausch And Lomb Inc	TIMOPTIC	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	018086-001	Approved Prior to Jan 1, 1982	4,195,085

International Patents for TIMOPTIC

See the table below for patents covering TIMOPTIC around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	288378
Austria	289788
Austria	289789
Austria	294830
Austria	295526

Supplementary Protection Certificates for TIMOPTIC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0227494	95C0013	Belgium		PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
0509752	C990041	Netherlands		PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
0509752	SPC/GB99/043	United Kingdom		PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
0509752	2000C/001	Belgium		PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
0509752	49/1999	Austria		PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306

TIMOPTIC (timolol ophthalmic) market dynamics and financial trajectory: pricing, demand drivers, exclusivity/patent overhang, channel mix, and competitive risk

Last updated: June 21, 2026

TIMOPTIC’s financial trajectory is shaped by (1) an old-generation, off-patent active (timolol) that is widely available as multisource ophthalmic drops, (2) sensitivity of U.S. pricing to generic entry and pharmacy channel contracting, and (3) ongoing substitution pressure from branded “same-molecule” offerings and reformulated/packaging variants rather than molecule innovation.

---

How does TIMOPTIC (timolol) make money in the U.S. and what drives demand?

Answer: TIMOPTIC revenues track routine glaucoma and ocular hypertension prescribing volume plus the level of brand versus generic retention in retail and institutional channels. Demand is supported by the chronic nature of glaucoma, but revenue per prescription is driven down by generic substitution and contracting.

Key demand drivers

• Disease prevalence and chronic therapy adherence
  • Glaucoma treatment is long-duration; timolol is typically used as monotherapy or add-on.
• Prescriber workflow and substitution
  • Timolol drops are formularized and treated as interchangeable at the molecule level; switching is common when payer preference changes.
• Target population
  • TIMOPTIC is positioned for ocular hypertension and open-angle glaucoma (and related conditions), where beta-blocker eye drops remain a core option in treatment sequences.

What typically constrains demand or shifts mix

• Side-effect and tolerance issues
  • Ocular irritation and systemic beta-blocker cautions can shift patients to other classes or limit use in at-risk populations.
• Payer formulary decisions
  • Pharmacy benefit managers favor lowest net cost generics and often steer use through step edits or tier placement.
• Device and regimen adherence
  • Drop size/viscosity and dosing frequency affect adherence and persistence, which can influence branded share in practice.

---

What does the competitive landscape look like for TIMOPTIC (timolol ophthalmic)?

Answer: Competition is dominated by generic timolol ophthalmic solutions and equivalents, with branded players attempting to differentiate through packaging, concentration options, and line extensions rather than new pharmacology.

Main competitor buckets

1. Generic timolol maleate eye drops
   • Multiple ANDA filers create pervasive substitution pressure.
2. Branded “same molecule” timolol products
   • Brands remain in market where contracting protects them or where specific strengths/dosing forms support limited differentiation.
3. Non-timolol glaucoma classes
   • Prostaglandin analogs and related agents often win formulary share over time; beta-blockers act as add-ons or fallback options depending on payer policy.

How competitive pricing is set

• Retail and pharmacy contracting
  • Brand pricing declines as market share shifts to generics; net pricing is sensitive to rebates and plan-specific incentives.
• Gross-to-net compression
  • Brand manufacturers typically face escalating tradeoffs: discounting to maintain share versus margin erosion.

---

When does TIMOPTIC lose exclusivity in the U.S., and what’s the practical impact of expiration?

Answer: For TIMOPTIC specifically, the practical exclusivity picture is dominated by the early expiration of timolol’s underlying composition/method protections. The U.S. ophthalmic market has largely moved to multisource timolol, so post-expiration dynamics are mostly about formulation/labeling and packaging patents rather than molecule exclusivity.

Practical “exclusivity” reality for an off-patent molecule

• Generic substitution already occurred for timolol ophthalmic
  • The brand’s revenue trajectory depends on non-molecule IP and channel strategy, not on waiting out a single molecule patent cliff.
• Remaining barriers are often limited to line extensions
  • If TIMOPTIC has protectable packaging, formulation, or method-of-use claims, they slow generic entry for that specific product configuration. However, timolol’s market is wide and typically supports fast multisource competition once product-specific barriers lapse.

---

What patents protect TIMOPTIC, and how many are relevant to market exclusivity?

Answer: TIMOPTIC’s protection is generally segmented into (1) legacy composition and basic dosing/medical-use concepts for timolol ophthalmics, and (2) narrower product-specific protections for particular strengths, concentrations, delivery characteristics, and manufacturing/formulation. In practice, the remaining relevant estate is often small relative to the broad multisource availability of timolol drops.

Patent estate categories that matter commercially

• Composition-of-matter and early formulation claims
  • Typically expired for older ophthalmic timolol products.
• Formulation, buffer system, and preservative system
  • Can protect specific drop characteristics if claims cover measurable formulation attributes.
• Method-of-use and labeling-related claims
  • Protect specific dosing regimens or clinical uses only if clearly claimed and enforced.
• Packaging and delivery device
  • Can block generics for particular container formats if claims tie to product features.

---

What patent litigation and Paragraph IV challenges have historically affected timolol eye drops like TIMOPTIC?

Answer: For older ophthalmic drugs, the most frequent litigation pattern is rapid ANDA entry litigation around product-specific formulation or method claims. For TIMOPTIC, the high-level market pattern is consistent with off-patent molecule dynamics where brand share erodes once product-specific barriers are cleared or challenged.

Typical litigation pathways that influence financial trajectory

• ANDA settlement agreements
  • Often lead to delayed launches and brand share stabilization during settlement windows.
• Consent decrees or staged entry
  • Can allow generics to enter at reduced share points before full line coverage.

What to watch in financial terms

• Launch timing effects
  • Generic entry causes sharp quarterly revenue and gross margin declines for the brand portion of the portfolio.
• Channel switching
  • A first generic entry often triggers formularies and pharmacy stocking changes that persist.

---

What is the Orange Book status of TIMOPTIC, and what does it imply for generic entry risk?

Answer: TIMOPTIC’s Orange Book relevance is primarily for any still-listed patents tied to its specific dosage forms/strengths. For timolol ophthalmics, the dominant implication is that generic entry risk is high because the active ingredient is widely available as multisource products.

How Orange Book status translates to launch risk

• If listed patents are expired or weakly enforceable
  • Expect continued generic availability and pricing pressure.
• If listed patents exist only for specific strengths
  • Expect partial brand protection and selective generic substitution.

---

How do formulation and packaging differences change the economics for TIMOPTIC?

Answer: Packaging and formulation variants can create short-lived revenue shields by slowing direct “drop-in” substitution and by supporting distinct billing codes, plan formularies, or patient preferences.

Commercially relevant differentiation levers

• Concentration and dosing regimen
  • Different strengths can be treated differently by payers, even within the same active.
• Container format
  • Preservation and container design can influence patient tolerance and substitution behavior.
• Stability and solution characteristics
  • If claims or clinical preferences exist, they can support a smaller niche within a broader interchangeable market.

Economic impact profile

• Short horizon
  • Differentiation tends to delay entry only until a multisource workaround is accepted.
• Limited margin uplift
  • Once generics match product characteristics, net pricing compresses quickly.

---

How does TIMOPTIC compare with other glaucoma therapies in market share and revenue stability?

Answer: TIMOPTIC is structurally less revenue-stable than newer, on-patent or biologically differentiated glaucoma therapies because it competes in an interchangeable, multisource segment.

Comparison framing

• Newer classes (prostaglandin analogs, Rho kinase inhibitors, combination fixed doses)
  • Often carry stronger branded share at initiation and can move treatment lines earlier.
• Timolol segment
  • More exposed to payer-driven substitution and pharmacy-level switching.

---

What is the financial trajectory likely to be for TIMOPTIC under current U.S. pricing dynamics?

Answer: The trajectory is a long, gradual decline in brand revenue share with episodic drops tied to generic or competitor mix changes. Margin trends are typically pressured by net price erosion, trade spending, and contracting, with limited upside unless product-specific IP, niche contracting, or label-based differentiation holds.

Typical quarter-to-quarter pattern for multisource ophthalmic brands

• Revenue: declines driven by generic share gains
• Gross margin: compressed by lower net pricing and promotional spend
• Volume: may remain stable longer than revenue if prescriptions persist but shift from brand to generics
• Portfolio effect: brands sometimes survive as “replenishment SKUs” for specific plan formularies

---

What generic entry scenarios are most likely for TIMOPTIC, and how would they hit revenue?

Answer: Revenue risk concentrates in scenarios where (1) product-specific formulation/packaging patents expire or are invalidated, or (2) additional multisource ANDA entrants secure broad pharmacy network coverage.

High-probability generic entry scenarios

1. Broad label-and-strength coverage
   • Many ANDAs cover multiple strengths, enabling substitution across the line.
2. Payer formulary steering
   • Even if brand remains on formulary, tiers and reimbursement rules can shift net utilization quickly.
3. Pharmacy stocking changes
   • When generics are cheapest at a point-of-sale, substitution can become automatic.

Expected financial impact mechanics

• Brand prescriptions fall first, then refill volume follows
• Net price continues to fall
• Gross-to-net ratio may worsen if brand attempts to defend share

---

Which business risks matter most to investors or licensors evaluating TIMOPTIC?

Answer: The dominant risks are (1) sustained generic pricing pressure, (2) limited incremental IP that blocks multisource entry broadly, and (3) channel leverage by large generic suppliers and pharmacy benefit managers.

Specific risk register

• IP risk: remaining patent estate is likely narrower than the full molecule footprint
• Regulatory risk: ANDA approvals tend to accelerate competition after barriers clear
• Commercial risk: net price is pulled down by contracting rather than only by wholesale market prices
• Manufacturing risk: not usually differentiating versus generic capacity for an established old molecule

---

Key patent and regulatory timeline framework for assessing TIMOPTIC revenue exposure

Answer: Use a product-specific approach: map each TIMOPTIC strength/dosage form to its latest Orange Book patents and any associated litigation/settlement calendar. For timolol ophthalmics, the “headline cliff” has already largely passed for the base active ingredient, so the revenue exposure is concentrated in residual patents tied to specific SKUs.

Timeline template (apply to each TIMOPTIC SKU)

• Orange Book listed patent expiration dates (composition/formulation/method)
• Last potential FDA exclusivity windows (if any)
• ANDA approval and first commercial launch dates
• Known litigation or settlement trigger dates
• Observed share and net price inflection points post-launch

---

What is the competitive financial outlook for TIMOPTIC versus substitute timolol products?

Answer: Substitute timolol products generally have structurally similar cost-of-goods and distribution profiles. The brand’s advantage is typically limited to short-term net contracting, SKU-specific differentiation, or historical formulary placement. Once substitution is established, the brand’s financial trajectory follows the industry pattern for off-patent ophthalmic drops.

Relative outcomes to expect

• Brand vs generic timolol
  • Brand share declines over time; generic drives net price lower.
• Line extension SKUs
  • Some SKUs may show slower decline if they maintain better plan placement or better tolerability/packaging fit.

---

Key Takeaways

• TIMOPTIC’s market dynamics are dominated by multisource timolol substitution, not by active-ingredient exclusivity.
• Financial trajectory is characterized by long-run revenue share erosion and gross-to-net compression, with sharper drops when new multisource coverage expands.
• Any remaining protection is likely SKU-specific (formulation/packaging/method label) and therefore creates uneven protection across strengths rather than broad line exclusivity.
• Generic entry risk is high once product-specific barriers clear, driven by ANDA approvals, pharmacy contracting, and payer formulary steering.

---

FAQs

1. Why do timolol eye drops lose brand share even if the brand remains on formulary?
   Formularies can keep a brand listed while tier placement, step edits, and pharmacy point-of-sale substitution shift utilization to lower net-cost generics.

2. Does packaging format for ophthalmic drops change generic substitution risk?
   Yes when patents or labeling tie to container, preservative system, or measurable product characteristics that generics cannot replicate under the same SKU constraints.

3. Are method-of-use patents for glaucoma relevant to generic entry for timolol?
   They can be relevant only if the specific use and regimen are clearly claimed and FDA labeling triggers are tied to those claims; enforcement is typically narrower than molecule-level protection.

4. What timing matters most for projecting TIMOPTIC revenue impact?
   The first commercial launch date(s) after patent clearance plus the subsequent quarter(s) when pharmacy networks and payer formularies fully switch.

5. How does competition from other glaucoma classes affect timolol revenue volatility?
   It tends to be gradual rather than sudden for timolol brands because timolol is used across lines of therapy, but formulary shifts can still reduce prescribing volume.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. Paragraph IV Certifications and Patent Certifications (ANDA-related framework). U.S. Food and Drug Administration. https://www.fda.gov/